Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
Benzinga Newsdesk 3 weeks ago
News
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation
- New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine
- AbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of development
- Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere®(mirvetuximab soravtansine-gynx)